Avalo Therapeutics (AVTX) Cash & Current Investments (2014 - 2026)
Avalo Therapeutics (AVTX) posted Cash & Current Investments of $57.2 million for Q1 2026, down 41.88% on a QoQ basis from $98.3 million in Q4 2025, and up 92080.65% year-over-year from N/an in Q1 2025.
Avalo Therapeutics (AVTX) Cash & Current Investments (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Cash & Current Investments history runs 13 years deep, the most recent figure standing at $57.2 million for Q1 2026.
- Quarterly Cash & Current Investments rose 92080.65% year-over-year to $57.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.2 million (up 92080.65% YoY) and the FY2025 annual result came in at $98.3 million, down 26.91% from the prior year.
- Cash & Current Investments was $57.2 million for Q1 2026 at Avalo Therapeutics, down from $98.3 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $134.5 million in Q4 2024 and bottomed at $4000.0 in Q1 2024.
- A 5-year average of $37.9 million and a median of $13.4 million in 2023 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2024 — Cash & Current Investments slumped 99.98% — and 2026, when it soared 92080.65%.
- Avalo Therapeutics' Cash & Current Investments stood at $15000.0 in 2022, then jumped by 49333.33% to $7.4 million in 2023, then surged by 1714.51% to $134.5 million in 2024, then declined by 26.91% to $98.3 million in 2025, then slumped by 41.88% to $57.2 million in 2026.
- Business Quant data shows AVTX's Cash & Current Investments at $57.2 million in Q1 2026, $98.3 million in Q4 2025, and $84.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Avalo Therapeutics | 396.51 Mn | 339.36 Mn | - | 57.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.15 Mn |
| Dec 31, 2025 | 98.34 Mn |
| Sep 30, 2025 | 84.74 Mn |
| Jun 30, 2025 | 70.99 Mn |
| Mar 31, 2025 | 62,000.00 |
| Dec 31, 2024 | 134.55 Mn |
| Sep 30, 2024 | 81.86 Mn |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | 7.42 Mn |
| Sep 30, 2023 | 10.18 Mn |
| Jun 30, 2023 | 6.31 Mn |
| Mar 31, 2023 | 16.69 Mn |
| Dec 31, 2022 | 15,000.00 |
| Sep 30, 2022 | 53,000.00 |
| Jun 30, 2022 | 14,000.00 |
| Mar 31, 2022 | 38.47 Mn |
| Dec 31, 2021 | 51,000.00 |
| Sep 30, 2021 | 164,000.00 |
| Jun 30, 2021 | 40.44 Mn |
| Mar 31, 2021 | 38.29 Mn |